Yoshishige Samukawa
Toshima, 1708633, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
The flavonoid Sudachitin regulates glucose metabolism via PDE inhibition.
Journal: Heliyon
Published: February 28, 2024
Impact of the lipase inhibitor orlistat on the human gut microbiota.
Journal: Obesity research & clinical practice
Published: February 17, 2023
Efficacy and Safety of Lipase Inhibitor Orlistat in Japanese with Excessive Visceral Fat Accumulation: 24-Week, Double-Blind, Randomized, Placebo-Controlled Study.
Journal: Advances in therapy
Published: September 03, 2018
Reduction of Excessive Visceral Fat and Safety with 52-Week Administration of Lipase Inhibitor Orlistat in Japanese: Long-Term Clinical Study.
Journal: Advances in therapy
Published: August 22, 2018
Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of Luseogliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus.
Journal: Biological & pharmaceutical bulletin
Published: August 04, 2017
Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment.
Journal: Clinical pharmacology in drug development
Published: August 02, 2017
SGLT2 inhibitor (Luseogliflozin): a new mechanism for treating type 2 diabetes mellitus and therapeutic potential to prevent the progression of diabetic complications.
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Published: November 03, 2016
Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, in humans.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: June 28, 2016
Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study.
Journal: Advances in therapy
Published: April 12, 2016
Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study.
Journal: Clinical pharmacology in drug development
Published: March 19, 2016
Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus.
Journal: Advances in therapy
Published: December 24, 2015
Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate diet.
Journal: Diabetes, obesity & metabolism
Published: October 14, 2015
Last Updated: 09/26/2026